Fenu Grazia, Griñán-Lisón Carmen, Etzi Federica, González-Titos Aitor, Pisano Andrea, Toledo Belén, Farace Cristiano, Sabalic Angela, Carrillo Esmeralda, Marchal Juan Antonio, Madeddu Roberto
Department of Biomedical Science, University of Sassari, 07100 Sassari, Italy.
Department of Biochemistry and Molecular Biology 2, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain.
Int J Mol Sci. 2025 Mar 21;26(7):2830. doi: 10.3390/ijms26072830.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death. Its poor prognosis is closely related to late-stage diagnosis, which results from both nonspecific symptoms and the absence of biomarkers for early diagnosis. MicroRNAs (miRNAs) exert a regulatory role in numerous biological processes and their aberrant expression has been found in a broad spectrum of diseases, including cancer. Cancer stem cells (CSCs) represent a driving force for PDAC initiation, progression, and metastatic spread. Our previous research highlighted the interesting behavior of miR-216a-5p and miR-125a-5p related to PDAC progression and the CSC phenotype. The present study aimed to evaluate the effect of miR-216a-5p and miR-125a-5p on the acquisition or suppression of pancreatic CSC traits. BxPC-3, AsPC-1 cell lines, and their CSC-like models were transfected with miR-216a-5p and miR-125a-5p mimics and inhibitors. Following transfection, we evaluated their impact on the expression of CSC surface markers (CD44/CD24/CxCR4), ALDH1 activity, pluripotency- and EMT-related gene expression, and clonogenic potential. Our results show that miR-216a-5p enhances the expression of CD44/CD24/CxCR4 while negatively affecting the activity of ALDH1 and the expression of EMT genes. MiR-216a-5p positively influenced the clonogenic property. MiR-125a-5p promoted the expression of CD44/CD24/CxCR4 while inhibiting ALDH1 activity. It enhanced the expression of , , and , while the clonogenic potential appeared to be affected. Comprehensively, our results provide further knowledge on the role of miRNAs in pancreatic CSCs. Moreover, they corroborate our previous findings about miR-216a-5p's potential dual role and miR-125a-5p's promotive function in PDAC.
胰腺导管腺癌(PDAC)是癌症相关死亡的第三大主要原因。其预后较差与晚期诊断密切相关,这是由非特异性症状以及缺乏早期诊断生物标志物所致。微小RNA(miRNA)在众多生物学过程中发挥调节作用,并且在包括癌症在内的广泛疾病中发现了它们的异常表达。癌症干细胞(CSC)是PDAC起始、进展和转移扩散的驱动力。我们之前的研究突出了miR-216a-5p和miR-125a-5p与PDAC进展及CSC表型相关的有趣行为。本研究旨在评估miR-216a-5p和miR-125a-5p对胰腺CSC特性获得或抑制的影响。用miR-216a-5p和miR-125a-5p模拟物和抑制剂转染BxPC-3、AsPC-1细胞系及其CSC样模型。转染后,我们评估了它们对CSC表面标志物(CD44/CD24/CxCR4)表达、ALDH1活性、多能性和EMT相关基因表达以及克隆形成潜力的影响。我们的结果表明,miR-216a-5p增强CD44/CD24/CxCR4的表达,同时对ALDH1活性和EMT基因表达产生负面影响。miR-216a-5p对克隆形成特性有积极影响。miR-125a-5p促进CD44/CD24/CxCR4的表达,同时抑制ALDH1活性。它增强了 、 和 的表达,而克隆形成潜力似乎受到影响。综合来看,我们的结果为miRNA在胰腺CSC中的作用提供了进一步的认识。此外,它们证实了我们之前关于miR-216a-5p潜在双重作用和miR-125a-5p在PDAC中的促进作用的发现。